药物涂层球囊血管成形术后阶梯式双联抗血小板降阶治疗(REC-CAGEFREE II):多中心、随机、开放标签、评估者盲、非劣效性试验
REC-CAGEFREE II为多中心、随机、开放标签、评估者盲、非劣效性试验,纳入中国41家医院1948例仅接受紫杉醇涂层球囊治疗的急性冠脉综合征成人(18-80岁)。随机1:1分为阶梯式DAPT降阶组(n=975,阿司匹林+替格瑞洛1个月,随后替格瑞洛单药5个月,再阿司匹林单药6个月)或标准DAPT组(n=973,阿司匹林+替格瑞洛12个月)。主要终点12个月净不良临床事件(全因死亡、卒中、心肌梗死、血运重建及BARC 3或5型出血)在降阶组87例(8.9%)vs 标准组84例(8.6%),差异0.36%,单侧95%CI上限2.47%,小于非劣效界值3.2%(P非劣效=0.013)。BARC 3或5型出血降阶组4例 vs 标准组16例(0.4% vs 1.6%,差异-1.19%,95%CI -2.07%至-0.31%,P=0.008);全因死亡、卒中、心肌梗死及血运重建降阶组84例 vs 标准组74例(8.6% vs 7.6%,差异1.05%,95%CI -1.37%至3.47%,P=0.396)。作者结论:在仅用药物涂层球囊治疗的急性冠脉综合征患者中,阶梯式DAPT降阶在净不良临床事件上非劣于12个月DAPT。
要点
- 急性冠脉综合征仅用紫杉醇涂层球囊治疗者,阶梯式DAPT降阶(阿司匹林+替格瑞洛1个月→替格瑞洛单药5个月→阿司匹林单药6个月)12个月净不良临床事件非劣于标准12个月DAPT(8.9% vs 8.6%,差异0.36%,单侧95%CI上限2.47%<3.2%,P非劣效=0.013)。
- 阶梯式降阶组BARC 3或5型出血4例(0.4%)vs 标准DAPT组16例(1.6%),差异-1.19%(95%CI -2.07%至-0.31%),P=0.008。
- 全因死亡、卒中、心肌梗死及血运重建降阶组84例(8.6%)vs 标准组74例(7.6%),差异1.05%(95%CI -1.37%至3.47%),P=0.396,未达统计学显著。
- 按预设 hierarchical 复合终点(全因死亡、卒中、心肌梗死、BARC 3型出血、血运重建、BARC 2型出血)采用 win ratio 法,降阶组 wins 14.4% vs 标准组10.1%,win ratio 1.43(95%CI 1.12至1.83),P=0.004。
- 符合方案集与意向性治疗分析结果相似。
适用人群与场景
- 纳入:18-80岁急性冠脉综合征成人,按国际药物涂层球囊共识仅接受紫杉醇涂层球囊治疗。
- 场景:中国41家医院,2021年11月27日至2023年1月21日。
处置流程与药物剂量
- 阶梯式DAPT降阶组(n=975):阿司匹林+替格瑞洛1个月,随后替格瑞洛单药5个月,再阿司匹林单药6个月。
- 标准DAPT组(n=973):阿司匹林+替格瑞洛12个月。
- 药物剂量、给药途径及频次:原文未写明。
研究设计与关键结果
- 研究类型:多中心、随机、开放标签、评估者盲、非劣效性试验(REC-CAGEFREE II),41家医院,样本量1948例(降阶组975例,标准组973例)。
- 人群特征:平均年龄59.2岁,男性74.9%,糖尿病30.5%,高出血风险20.6%;60.9%的靶病变位于小血管,17.8%为支架内再狭窄;药物涂层球囊平均直径2.72 mm(标准差0.49)。
- 主要终点(12个月净不良临床事件:全因死亡、卒中、心肌梗死、血运重建及BARC 3或5型出血,意向性治疗人群):降阶组87例(8.9%)vs 标准组84例(8.6%),差异0.36%,单侧95%CI上限2.47%,P非劣效=0.013。
- BARC 3或5型出血:降阶组4例(0.4%)vs 标准组16例(1.6%),差异-1.19%(95%CI -2.07%至-0.31%),P=0.008。
- 全因死亡、卒中、心肌梗死及血运重建:降阶组84例(8.6%)vs 标准组74例(7.6%),差异1.05%(95%CI -1.37%至3.47%),P=0.396。
- 预设 hierarchical 复合终点(全因死亡、卒中、心肌梗死、BARC 3型出血、血运重建、BARC 2型出血)win ratio 法:降阶组 wins 14.4% vs 标准组10.1%,win ratio 1.43(95%CI 1.12至1.83),P=0.004。
- 符合方案集与意向性治疗分析结果相似。
证据类型、等级与局限
- 证据类型:多中心、随机、开放标签、评估者盲、非劣效性试验。
- 非劣效界值:单侧95%CI绝对风险差异上限小于3.2%。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于急性冠脉综合征且仅用紫杉醇涂层球囊治疗、符合试验条件的患者,作者结论认为阶梯式DAPT降阶在12个月净不良临床事件上非劣于12个月DAPT。
- 阶梯式降阶方案为阿司匹林+替格瑞洛1个月,随后替格瑞洛单药5个月,再阿司匹林单药6个月;标准方案为阿司匹林+替格瑞洛12个月。
- 降阶组BARC 3或5型出血更低(0.4% vs 1.6%),全因死亡、卒中、心肌梗死及血运重建两组无显著差异(8.6% vs 7.6%,P=0.396)。
指南或共识出处
- REC-CAGEFREE II,ClinicalTrials.gov NCT04971356。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate whether a less intense antiplatelet regimen could be used for people receiving drug coated balloons.
DESIGN: Multicentre, randomised, open label, assessor blind, non-inferiority trial (REC-CAGEFREE II).
SETTING: 41 hospitals in China between 27 November 2021 and 21 January 2023.
PARTICIPANTS: 1948 adults (18-80 years) with acute coronary syndrome who received treatment exclusively with paclitaxel-coated balloons according to the international drug coated balloon consensus.
INTERVENTIONS: Participants were randomly assigned (1:1) to either the stepwise dual antiplatelet therapy (DAPT) de-escalation group (n=975) consisting of aspirin plus ticagrelor for one month, followed by five months of ticagrelor monotherapy, and then six months of aspirin monotherapy, or to the standard DAPT group (n=973) consisting of aspirin plus ticagrelor for 12 months.
MAIN OUTCOME MEASURES: The primary endpoint was net adverse clinical events (all cause death, stroke, myocardial infarction, revascularisation, and Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding) at 12 months in the intention-to-treat population. Non-inferiority was established if the upper limit of the one sided 95% confidence interval (CI) for the absolute risk difference was smaller than 3.2%.
RESULTS: The mean age of participants was 59.2 years, 74.9% were men, 30.5% had diabetes, and 20.6% were at high bleeding risk. 60.9% of treated lesions were in small vessels, and 17.8% were in-stent restenosis. The mean drug coated balloon diameter was 2.72 mm (standard deviation 0.49). At 12 months, the primary endpoint occurred in 87 (8.9%) participants in the stepwise de-escalation group and 84 (8.6%) in the standard group (difference 0.36%; upper boundary of the one sided 95% CI 2.47%; Pnon-inferiority=0.013). In the stepwise de-escalation versus standard groups, BARC type 3 or 5 bleeding occurred in four versus 16 participants (0.4% v 1.6%, difference -1.19% (95% CI -2.07% to -0.31%), P=0.008), and all cause death, stroke, myocardial infarction, and revascularisation occurred in 84 versus 74 participants (8.6% v 7.6%, difference 1.05% (95% CI -1.37% to 3.47%), P=0.396). Treated as having hierarchical clinical importance by the win ratio method, more wins were noted with the stepwise de-escalation group (14.4% wins) compared with the standard group (10.1% wins) for the predefined hierarchical composite endpoint of all cause death, stroke, myocardial infarction, BARC type 3 bleeding, revascularisation, and BARC type 2 bleeding (win ratio 1.43 (95% CI 1.12 to 1.83), P=0.004). Results from the per-protocol and the intention-to-treat analysis were similar.
CONCLUSIONS: Among participants with acute coronary syndrome who could be treated by drug coated balloons exclusively, a stepwise DAPT de-escalation was non-inferior to 12 month DAPT for net adverse clinical events.
TRIAL REGISTRATION: Clinicaltrials.gov NCT04971356.
参考来源
- Gao C, Zhu B, Ouyang F, et al. Stepwise dual antiplatelet therapy de-escalation in patients after drug coated balloon angioplasty (REC-CAGEFREE II): multicentre, randomised, open label, assessor blind, non-inferiority trial. BMJ. 2025. PMID: 40164448. doi:10.1136/bmj-2024-082945
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。